Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | BAY1436032: IDH1 inhibition in IDH1-mutated AML

Michael Heuser • 2 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia BAY1436032

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, reports the Phase I safety and efficacy results of the mutant IDH1 inhibitor, BAY1436032 in subjects with IDH1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael Heuser

3:13
Final results of BRIGHT AML 1003
Michael Heuser • 12 Jun 2020
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019
2:51
AML: mutant IDH1 inhibitor HMS-101
Michael Heuser • 25 Oct 2019
1:30
The clinical application of MRD testing in AML
Michael Heuser • 1 Jun 2019

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals